identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma.cancer medicine. 2021 aug 21.
bortezomib activation of mtorc1c1 pathway mediated by nox2-drived reactive oxygen species results in apoptosis in primary dorsal root ganglion neurons. experimental cell research, feb. 2021, 400, 112494.
nomogram for predicting the overall survival of adult patients with primary gastrointestinal diffuse large b cell lymphoma: a seerbased study.frontiers in oncology. july 2020, volume 10.
abnormal ptbp1 expression sustains the disease progression of multiple myeloma. disease markers. 2020, jun.article id 4013658.
mir-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(adp-ribose) polymerase1 acetylation. leukemia & lymphoma. 2020, 62(1): 136-146.
daunorubicin-loaded cdte qds conjugated with anti-cd123 mabs: a novel delivery system for myelodysplastic syndromes treatment. int j nanomedicine. 2020 jan 24;15:521-536.
comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation a systematic review and network meta-analysis.jama network open. 2020. 3(10):e2017652.
bag3 regulates multiple myeloma cell proliferation through foxm1/rb/e2f axis.cancer gene ther. 2020 02;27.
vincristine-loaded platelets coated with anti-cd41 mabs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia. biomater sci. 2019 nov 1;7(11):4568-4577.
higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma. transl cancer res. 2019;8(5):2099-2106.
trem1/dap12-based car-t cells show potent antitumor activity. immunotherapy.2019 aug;11(12):1043-1055.
prognostic value of 1q21 gain in multiple myeloma. clin lymphoma myeloma leuk. 2019 03;19(3).
development of follicular lymphoma after treatment of diffuse large b-cell lymphoma: two case reports with review of literature. int j clin exp pathol. 2018;11(1):324-332.
pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. clinica chimica acta. 481 (2018) 34–41.
doxorubicin-loaded peg-cdte quantum dots as a smart drug delivery system for extramedullary multiple myeloma treatment. nanoscale res lett. 2018-11.13(1):373.
acute lymphoblastic leukemia in a patient with igg4-related disease. pharmazie. 73: 418-421 (2018).
anti-cd22-conjugated cdte qds co-loaded with doxorubicin and gambogic acid: a novel platform for lymphoma treatment.rsc adv. 2017, jul; 7, 33905–33913.
characteristics and mutation analysis of ph-positive leukemia patients with t315i mutation receiving tyrosine kinase inhibitors oncotargets and therapy. 2017:10 4731–4738.
the association between expression of hypoxia inducible factor1α and multi-drug resistance of acute myeloid leukemia. transl cancer res. 2017;6(1):198-205.
the polymorphism of jak2 rs56118985 may be a predictive marker of the treatment responses of acute myeloid leukemia patients. transl cancer res. 2017;6(4):779-787.
expression of magec1/ct7 provides prognostic information in multiple myeloma. leukemia & lymphoma. 2017-01.58(1):244-246.
